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The SENTRY Antimicrobial Surveillance Program has incorporated molecular strain typing and resistance
genotyping as a means of providing additional information that may be useful for understanding pathogenic
microorganisms worldwide. Resistance phenotypes of interest include multidrug-resistant pathogens, extended-
spectrum b-lactamase (ESBL)–producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant enterococci, and fluoroquinolone-resistant (FQR) strains of gram-negative ba-
cilli and Streptococcus pneumoniae. Clusters of 2 isolates within a given resistance profile that are linked
temporally and by hospital location are flagged for DNA fingerprinting. Further characterization of organisms
with respect to resistance genotype is accomplished with use of polymerase chain reaction and DNA sequencing.
This process has been highly successful in identifying clonal spread within clusters of multiresistant pathogens.
Between 50% and 90% of MRSA clusters identified by phenotypic screening contained evidence of clonal
spread. Among the Enterobacteriaceae, ESBL-producing strains of Escherichia coli and Klebsiella pneumoniae
are the most common pathogens causing clusters of infection, and ∼50% of recognized clusters demonstrate
clonal spread. Clusters of Pseudomonas aeruginosa, Acinetobacter species, and Stenotrophomonas maltophilia
have been noted with clonal spread among patients with urinary tract, respiratory, and bloodstream infections.
Characterization of mutations in the FQR-determining region of phenotypically susceptible isolates of E. coli
and S. pneumoniae has identified first-stage mutants among as many as 40% of isolates. The ability to
characterize organisms phenotypically and genotypically is extremely powerful and provides unique infor-
mation that is important in a global antimicrobial surveillance program.
Antimicrobial resistance is a problem of worldwide
magnitude [1]. With the increased interest and concern
regarding antimicrobial resistance, there are now several
major programs that have been organized to conduct
surveillance for antimicrobial resistance on a national
and international basis. Examples of some of the more
prominent surveillance programs include the National
Nosocomial Infection Surveillance system, Project
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ICARE (Intensive Care Antimicrobial Resistance Epi-
demiology), the SENTRY Antimicrobial Surveillance
Program, the Surveillance and Control of Pathogens of
Epidemiologic Importance project, the Alexander Pro-
ject, and The Surveillance Network [2–7]. Each of these
programs involves the use of conventional broth- and
agar-based antimicrobial susceptibility testing methods
to provide a phenotypic profile of the response of
microbial pathogens to an array of antimicrobial agents.
The data available from each of these programs build
on those of the others and provide a compelling body
of information that underscores the global nature of
the resistance problem [2–6]. This information is useful
for alerting the public, as well as the medical and sci-
entific community, to the problem of antimicrobial re-
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Table 1. Genotypic methods for epidemiological typing of microorganisms in the SENTRY program.
Method Comments Examples
Plasmid analysis Plasmids may be digested with restric-
tion endonuclease enzymes; useful in
tracking spread of resistance genes
Staphylococci, Enterobacteriaceae
Restriction endonuclease analysis of
chromosomal DNA with conventional
electrophoresis
Large number of bands; difficult to inter-
pret; not amenable to computer analy-
sis; a comparative typing method only
Enterococci, Staphylococcus au-
reus, Clostridium difficile, Can-
dida species
Genome restriction fragment-length poly-
morphism analysis: ribotyping, insertion
sequence probe fingerprinting
Fewer bands; amenable to automation
and computer analysis; sequence-
based profiles; library typing methods
Enterobacteriaceae, staphylococci,
and Pseudomonas aeruginosa,
Candida species
PCR-based methods: repetitive-elements
PCR spacer typing, selective amplifica-
tion of genome restriction fragments,
multilocus allelic sequence-based
typing
Crude nucleic acid extracts and small
amounts of DNA may suffice; amena-
ble to computer analysis
Enterobacteriaceae, Acinetobacter
species, staphylococci
Pulsed-field gel electrophoresis Fewer bands; amenable to computer
analysis; very broad application; may
be used as either a comparative or li-
brary typing system
Enterobacteriaceae, staphylococci,
enterococci, Candida species
NOTE. The table contains examples of available methods and applications and is not intended to be all inclusive (adapted from [11]).
Table 2. Molecular methods for detecting antimicrobial resistance in the SENTRY program.
Antimicrobial agent(s) Organisms Gene Detection methods
Methicillin, oxacillin Staphylococci mec Aa DNA probe, branched-chain
DNA probe, PCR
Vancomycin Enterococci van A, B, C, Db DNA probe, PCR
b-Lactams Enterobacteriaceae, Haemophilus
influenzae, other nonenteric
gram-negatives
blaTEM and blaSHV
c DNA probe, PCR and RFLP,
PCR and sequencing, iso-
electric focusing
Quinolones Enterobacteriaceae, H. influenzae,
gram-positive cocci
Point mutations in gyr A,
gyr B, par C, and par E
PCR and sequencing
NOTE. RFLP, restriction fragment-length polymorphism. Table is adapted from [9].
a mec A encodes for the altered penicillin binding protein 2a; phenotypic methods may require 48-h incubation to detect resistance
and are !100% sensitive. Detection of mec A has potential for clinical application in specific circumstances.
b Vancomycin resistance in enterococci may be related to 1 of 4 distinct genotypes, of which van A and van B are most important.
Genotypic detection of resistance is useful in validation of phenotypic methods.
c The genetic basis of resistance to b-lactam antimicrobials is extremely complex. The blaTEM and blaSHV genes are the 2 most common
sets of plasmid-encoded b-lactamases. The presence of either a blaTEM or blaSHV gene implies ampicillin resistance. Variants of the blaTEM
and blaSHV genes (extended-spectrum b-lactamases) may also encode for resistance to a range of third-generation cephalosporins and to
monobactams.
sistance and for designing empirical treatment regimens and
formulating possible preventive strategies [1].
Although useful as a screen for detecting certain resistance
profiles and for selecting potentially useful therapeutic agents,
conventional antimicrobial susceptibility testing methods are
insensitive for tracing the spread of individual strains within a
hospital or region and for detecting resistance mechanisms that
may be present at low levels in a population of organisms and
where selection or induction of resistance is necessary before
the resistant phenotype is expressed [8, 9]. The techniques of
molecular biology have proven to be invaluable in the diagnosis
of many infectious diseases and provide further insight into
the mechanisms of antimicrobial resistance and the clonal
spread of many key microbial pathogens [8–12]. Comprehen-
sive molecular typing of organisms collected in a global sur-
veillance program may also provide information regarding the
emergence and distribution of specific pathogenic strains as
well as the spread of resistance determinants [13–15].
Among the active surveillance programs, the SENTRY Anti-
microbial Surveillance Program has incorporated molecular
strain typing and resistance genotyping as a means of providing
additional information that may be useful for understanding
pathogenic microorganisms worldwide. Examples of this work
are provided in other manuscripts in this supplement. The
material discussed herein will provide an overview of the meth-
ods used, the process by which molecular methods are applied
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Table 3. Comparison of ribotyping and pulsed-field gel electrophoresis (PFGE) for
typing bacterial isolates.
Organism
No. of
Index of
discrimination
Ribogroups PFGE types Ribotyping PFGE
Staphylococcus aureus (n p 57) 30 28 0.93 0.91
Escherichia coli (n p 97) 38 72 0.78 0.96
Klebsiella pneumoniae (n p 53) 42 50 0.97 0.98
Pseudomonas aeruginosa (n p 12) 4 10 0.73 0.89
Enterococcus faecium (n p 17) 8 14 0.80 0.95
Enterobacter cloacae (n p 43) 42 38 0.95 0.97
NOTE. Table is adapted from [18].
Table 4. Molecular analysis of organism clusters exhibiting multidrug resistance (MDR) patterns observed during
1999: SENTRY objective A (bloodstream infections).
Organism
Total
isolatesa
No. of
MDR clusters
(no. of isolates)
No. of
sites with
MDR clusters
No. of MDR
clusters with
possible clonal spread
(no. of isolates)b
No. of
sites with
MDR clones
Staphylococcus aureus 2348 49 (250) 34 35 (143) 28
Klebsiella pneumoniae 677 14 (51) 12 8 (20) 7
Escherichia coli 1755 14 (53) 10 6 (22) 6
Enterococcus faecium 157 4 (11) 4 2 (7) 2
Acinetobacter baumanii 125 4 (12) 3 2 (6) 2
Pseudomonas aeruginosa 477 3 (12) 3 3 (7) 3
Enterobacter aerogenes 84 2 (9) 2 2 (4) 2
Enterobacter cloacae 265 1 (4) 1 1 (3) 1
Stenotrophomonas maltophilia 64 1 (3) 1 1 (2) 1
Proteus mirabilis 140 1 (2) 1 1 (2) 1
Streptococcus pneumoniae 455 1 (3) 1 1 (2) 1
Total 6547 94 (410) 44c 62 (218) 33c
a Total number of isolates of each species tested in objective A, 1999 (from the United States, Canada, Latin America, Europe, Israel,
and Turkey; total of 72 study sites).
b Possible clonal spread is defined as isolates with identical ribotypes and pulsed-field gel electrophoresis profiles.
c Some sites had more than 1 cluster/clone.
in a comprehensive surveillance program, and additional ex-
amples highlighting instances in which molecular characteri-
zation has proved useful for understanding groups of resistant
pathogens.
MOLECULAR METHODS USED IN THE SENTRY
PROGRAM
The laboratory characterization of microorganisms to provide
evidence of biological and genetic relatedness is frequently of
use to physicians, microbiologists, and epidemiologists as an
aid in the investigation of infectious diseases [9]. The need to
determine the relatedness of organisms may arise during an
outbreak investigation in which a cluster of infections due to
organisms of the same species and antimicrobial resistance phe-
notype is identified and in which the goals are to determine
clonal spread in a microenvironment and identify the source
of infection [16].
Alternatively, epidemiological surveillance conducted over
time requires the monitoring of clonal spread and prevalence
of strains within a population as an aid in long-term evaluation
of control strategies or for detection and monitoring of emerg-
ing infections [13, 14, 17]. Likewise, characterization of the
molecular and biological mechanisms of antimicrobial resis-
tance (resistance genotyping) may enhance the ability of micro-
biologists and epidemiologists to track the spread of antimi-
crobial resistance within and among health care facilities and
communities [8].
Microbial strain delineation by DNA-based typing methods
(DNA fingerprinting) is a very powerful tool that contributes
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Table 5. Molecular analysis of organism clusters exhibiting multidrug resistance (MDR) patterns observed during
1999: SENTRY objective C (pneumonia in hospitalized patients).
Organism
Total
isolatesa
No. of
MDR clusters
(no. of isolates)
No. of
sites with
MDR clusters
No. of MDR
clusters with
possible clonal spread
(no. of isolates)b
No. of
sites with
MDR clones
Staphylococcus aureus 975 13 (70) 13 12 (53) 12
Pseudomonas aeruginosa 859 7 (32) 6 4 (18) 3
Acinetobacter baumanii 76 7 (29) 6 5 (18) 4
Stenotrophomonas maltophilia 117 6 (25) 6 5 (13) 5
Klebsiella pneumoniae 244 2 (12) 2 1 (2) 1
Klebsiella oxytoca 63 2 (9) 2 0 0
Citrobacter koseri 20 1 (2) 1 0 0
Enterobacter aerogenes 67 1 (2) 1 0 0
Escherichia coli 100 1 (3) 1 0 0
Acinetobacter calcoaceticus 20 1 (12) 1 1 (10) 1
Total 1582 41 (196) 26c 28 (114) 21c
a Total number of isolates of each species tested in objective C, 1999 (from the United States, Canada, Latin America, Europe, Israel,
and Turkey; total of 72 study sites).
b Possible clonal spread is defined as isolates with identical ribotypes and pulsed-field gel electrophoresis profiles.
c Some sites had more than 1 cluster/clone.
Table 6. Molecular analysis of organism clusters exhibiting multidrug resistance (MDR) patterns observed
during 1999; SENTRY objective D (wound infections).
Organism
Total
isolatesa
No. of
MDR clusters
(no. of isolates)
No. of
sites with
MDR clusters
No. of MDR
clusters with possible
clonal spread
(no. of isolates)b
No. of
sites with
MDR clones
Staphylococcus aureus 217 12 (49) 12 6 (21) 6
Pseudomonas aeruginosa 90 4 (13) 4 1 (2) 1
Escherichia coli 83 3 (9) 3 2 (4) 2
Enterobacter cloacae 33 2 (6) 2 1 (4) 1
Acinetobacter baumanii 20 2 (4) 2 1 (2) 1
Klebsiella pneumoniae 25 1 (2) 1 0 0
Klebsiella oxytoca 5 1 (2) 1 0 0
Streptococcus pyogenes 17 1 (11) 1 1 (7) 1
Total 490 26 (96) 17c 12 (40) 9c
a Total number of isolates of each species tested in objective D, 1999 (from the United States, Canada, Latin America, Europe,
Israel, and Turkey; total of 72 study sites).
b Possible clonal spread is defined as isolates with identical ribotypes and pulsed-field gel electrophoresis profiles.
c Some sites had more than one cluster/clone.
to our understanding of outbreaks and recurrent infection [11].
Investigators have used a variety of DNA-based methods to
genotype microbial pathogens (table 1). All of these methods
depend on the generation of a distinct pattern or DNA “finger-
print” that may be visualized by ethidium bromide staining or
by nucleic acid hybridization. An additional level of discrim-
ination may be achieved by DNA sequencing to detect single
base-pair changes. This approach is particularly useful in char-
acterizing various antimicrobial resistance genes and mutations
causing resistance to specific classes of antimicrobial agents [8]
(table 2).
Genotyping methods may be broken down into 2 broad
categories: comparative methods and library typing methods
[12]. Both are useful in a surveillance program. Comparative
typing methods are most often applied in the setting of an
outbreak investigation as an aid in addressing the short-term
control of transmission in a hospital or community setting. In
this situation a typing method is used to compare a limited
number of isolates collected over a relatively short period (days
to weeks) to identify clonally related (epidemic) strains and
unrelated (sporadic) strains. The performance requirements for
a comparative typing system are good reproducibility within a
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Table 7. Common pulsed-field gel electrophoresis (PFGE)
patterns of multidrug-resistant/methicillin-resistant Staphylo-
coccus aureus bloodstream isolates contained within the 2
most common ribotypes, including geographic distribution.
Ribotype
PFGE
typea
No. of
isolates Location(s)
184-5 I 26 Singapore, Hong Kong, Australia
II 9 France, Japan, South Africa
III 13 Italy, Hong Kong, Singapore,
Texas
IV 20 France, Poland, South Africa,
Italy, Portugal
V 9 France, Taiwan
VI 8 Michigan, Illinois, New York,
Missouri, Virginia
VII 7 New York, California, Texas
893-5 I 24 Portugal, Italy, Argentina, Brazil,
Chile
NOTE. Table is adapted from [13].
a Each PFGE type represents strains that differ by 3 or fewer bands or
share 180% similarity (DENDRON).
single assay, a high index of discrimination (10.95), and the
ability to provide results for each organism (full typeability)
[18]. Several different DNA-based typing methods fulfill these
criteria, but the most widely used method for comparative
typing is pulsed-field gel electrophoresis (PFGE) [11, 12]. PFGE
is used as a comparative typing method in the SENTRY pro-
gram because of its excellent discriminatory power and broad
applicability for most gram-negative and gram-positive organ-
isms [18].
Library typing methods are most useful in the context of a
prospective epidemiologic surveillance effort. The collection
and characterization of large numbers of organisms over a pro-
longed period (months to years) require the use of strain mark-
ers with a standardized nomenclature and with high repro-
ducibility over time. The patterns must be amenable to
computer-based analysis and storage, and the discriminatory
power of the method must be balanced against the evolutionary
stability of the organism of interest to allow the recognition of
clonal dispersion over more prolonged periods [12]. Library
typing systems are used to aid in the monitoring of the geo-
graphic spread and prevalence shifts of epidemic and endemic
clones and in the long-term evaluation of preventive strategies
[12].
Because surveillance studies such as SENTRY typically in-
volve hundreds to thousands of organisms collected over an
extended period, the use of a method that is highly standardized
and provides a high throughput is essential to generate mean-
ingful results. These performance characteristics are met by the
RiboPrinter Microbial Characterization System (Qualicon),
which is a commercially available automated system that per-
forms ribotyping and uses computer-assisted pattern analysis
to ensure a high degree of standardization, excellent run-to-
run comparability, high throughput, and reduction in labor
costs [18]. Ribotyping by means of the RiboPrinter displays a
high degree of typeability but generally less discrimination than
PFGE [18] (table 3). The RiboPrinter is used as the primary
(library) typing system in the SENTRY program [13–15, 17].
Isolates sharing the same ribotype profile are further discrim-
inated by PFGE [13, 14, 18].
Molecular methods may be used to detect specific antimicro-
bial resistance genes (resistance genotyping) in a wide variety of
organisms and when coupled with DNA fingerprinting have
made substantial contributions to our understanding of the ge-
netics of antimicrobial resistance and the spread of resistance
determinants [8–10]. The resistance mechanisms in gram-neg-
ative and gram-positive bacteria are both complex and numerous
and include enzymatic inactivation, target alteration, decreased
uptake, and increased efflux. Organisms may contain several dif-
ferent resistance genes, and subtle variations (e.g., point muta-
tions) in certain genes may result in the expression of extremely
broad-spectrum resistance factors such as extended-spectrum b-
lactamases (ESBLs) [10].
Despite this complexity, DNA probe– or PCR-based methods
have proved extremely effective in detecting antimicrobial resis-
tance genes, including those encoding for methicillin resistance
in staphylococci (mec A), vancomycin resistance in enterococci
(van A, B, C, D), b-lactam resistance in Enterobacteriaceae
(blaTEM, blaSHV), and fluoroquinolone resistances in gram-negative
bacilli and gram-positive cocci (point mutations in gyr A, gyr B,
par C, and par E), to name a few (table 2) [10]. The use of
isoelectric focusing to define the complement of b-lactamase
enzymes produced by an organism, followed by PCR and se-
quencing of the amplified product, has been useful in identifying
new b-lactamases and in detecting the transmission of resistance
genes among different strains and species [19, 20].
Likewise, characterization of the quinolone-resistance-deter-
mining region (QRDR) of gram-negative and gram-positive bac-
teria may be accomplished by amplification of the gyr A, gyr B,
par C, and par E genes by PCR, followed by sequencing of the
amplicons to detect point mutations [21–23]. Because fluoro-
quinolone resistance arises in a stepwise manner dependent upon
the number of QRDR mutations, molecular characterization of
the QRDR may be useful, not only to confirm the mechanism
of high-level fluoroquinolone resistance but also to determine
the frequency of first-step mutations, which may not produce
overt resistance but will create a population of organisms that
will rapidly develop high-level resistance once a second mutation
is acquired [21].
Antimicrobial resistance genotyping is used selectively in the
SENTRY program to further characterize groups of organisms
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Figure 1. Ribotype and pulsed-field gel electrophoresis (PFGE) profiles
of 7 methicillin-resistant Staphylococcus aureus isolates. The 2 isolates
with ribotype 266-4 demonstrate indistinguishable PFGE profiles (A). The
5 isolates encompassed by ribotype designation 184-4 represent 3 dif-
ferent strains by PFGE analysis: B (3 isolates), E (1 isolate), and D (1
isolate). This example demonstrates the usefulness of employing both
molecular typing methods.
with specific resistance phenotypes and to identify subpopu-
lations of apparently susceptible organisms that may be at risk
of becoming highly resistant (e.g., first-step QRDR mutants).
In addition, the combination of resistance genotyping with
DNA fingerprinting has proved to be a powerful means of
characterizing the epidemiology of antimicrobial resistance
among nosocomial and community-acquired pathogens [21,
22, 24–27].
APPLICATION OF MOLECULAR METHODS IN A
GLOBAL SURVEILLANCE SYSTEM
Rationale. In any surveillance program the phenotypic char-
acterization of microorganisms and identification of clusters of
certain species and resistance phenotypes is the primary role
of the microbiology laboratory. In this way, the surveillance
laboratory serves as an “early warning system,” alerting the
submitting institution of a potential problem with resistant
organisms in the patient population [28, 29]. For most of the
existing antimicrobial resistance surveillance programs, whether
they are local, regional, national, or international in scope, the
process does not go much beyond phenotypic characterization
and reporting. However, to be of maximum service to indi-
vidual hospitals, regions, or countries, the surveillance labo-
ratory must go one step further and provide a rapid assessment
of microbial clonality by molecular typing [11, 29, 30].
The rapid emergence and dissemination of drug resistance
among bacteria has raised the call for control of these pathogens
to be a strategic priority for hospitals on a global scale [31],
and determination of clonality within a phenotypically identical
cluster may have a direct impact on the method of intervention
[16, 30]. If the clustered isolates are distinct genotypically, then
the clustering may be due to chance alone, to grouping of
several highly susceptible patients together, or to excessive drug
pressure resulting in the selection of a resistant phenotype
within a group of unrelated isolates. Clonal dissemination of
a resistant strain illustrates the need for more extensive inves-
tigation to identify the mechanism of spread and for renewed
attention to infection control efforts.
The identification of an endemic resistance problem that is
due to the occurrence of multiple small clusters of organisms
requires a composite approach of antimicrobial restriction and
focused use of barrier infection-control precautions [30]. Ad-
ditional determination of the resistance genotype provides in-
sight into the mechanism of resistance and may be necessary
to understand whether a resistance problem is due to the trans-
mission of resistance genes from organism to organism (control
by antimicrobial restriction) or transmission of a single resistant
strain from person to person (control by infection-control pre-
cautions). Identification of a subpopulation of organisms that
are first-step mutants in a multistep pathway leading to high-
level resistance (e.g., fluoroquinolone resistance) may trigger
strategies that could both prevent the development of high-
level resistance and improve therapy overall [21].
On a broader scale, identification of resistant clones with
extensive geographic distribution may provide insight into
strain virulence and pathogenesis and also may result in public
health interventions such as vaccination and antimicrobial re-
strictions aimed at reducing the spread of the pathogen and
the resistance problem [13, 14, 32, 33].
All of the above considerations provide the rationale for the
comprehensive molecular typing program that is integral to the
SENTRY Antimicrobial Surveillance Program. Each year hun-
dreds of organisms are molecularly characterized (tables 4–6),
the information is reported to the individual participating cen-
ters, and the aggregated data are used to help describe the epi-
demiology of resistant pathogens such as methicillin-resistant
Staphylococcus aureus (MRSA) [13, 14], vancomycin-resistanten-
terococci [34], and ESBL-producing gram-negative bacilli [15].
Process for selecting organisms for molecular characteri-
zation in the SENTRY program. Each year (1997–1999)
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Table 8. Molecular characterization of 6 Escherichia coli and 13 Klebsiella pneumoniae
strains having ESBL enzymes isolated from BSIs and UTIs at medical centers in 5 Latin
American countries.
Species,
medical center Country Infection
Molecular typing
IEF resultsRibotype PFGE pattern
E. coli
040 Argentina BSI 252-1 ND 5.4, 7.0, 7.6
042 Chile BSI 241-4 ND 5.4, 7.0
046 Brazil BSI 241-4 M 5.4, 8.0
048 Brazil BSI 182-2 G 5.4, 7.0, 7.6
048 Brazil BSI 182-2 G 5.4, 7.0, 8.2
048 Brazil BSI 182-2 G 5.4, 7.0, 8.2
K. pneumoniae
039 Argentina BSI 614-1 G 5.4, 6.8, 7.6
039 Argentina BSI 614-1 G 5.4, 6.8, 7.6
039 Argentina BSI 621-1 C 5.4, 6.5, 6.8, 7.6, 8.0
039 Argentina BSI 621-1 C 5.4, 6.5, 6.8, 7.6, 8.0
041 Brazil BSI 204-1 G 5.4, 7.0, 7.6
041 Brazil BSI 204-1 G 5.4, 7.0, 8.2
041 Brazil BSI 204-1 G 7.6, 8.2
041 Brazil UTI 204-1 B 5.4, 7.6, 8.2
041 Brazil UTI 622-3 E ND
044 Colombia BSI 746-3 ND 5.4, 7.6, 8.2
044 Colombia BSI 746-6 ND 5.4, 7.6, 8.2
044 Colombia BSI 324-2 ND 7.0, 8.2
045 Mexico BSI 756-7 ND 5.4, 7.0
NOTE. BSI, bloodstream infection; ESBL, extended-spectrum b-lactamase; IEF, isoelectric focus; ND,
not done; UTI, urinary tract infection. Table is adapted from [25–27].
∼30,000 bacterial isolates are identified and tested for suscep-
tibility and resistance to up to 70 different antimicrobial agents
by the SENTRY coordinating laboratories in Iowa City, Iowa,
and Adelaide, Australia. The antimicrobial susceptibility test
(AST) data and identification data for each organism are re-
viewed on a weekly basis by the laboratory directors. When
unusual resistance profiles and identifications that are incon-
sistent with the AST patterns are detected, the AST and iden-
tification are repeated to ensure a high degree of accuracy.
The phenotypic data are grouped according to the submitting
center, and demographic data (age, sex, hospital location, date
of admission, date of infection, underlying disease) are examined
concurrently with the AST and identification information. Mul-
tidrug-resistant (MDR) pathogens are defined as those organisms
that are resistant to at least 4 different classes of antimicrobial
agents. Other resistance phenotypes that are of interest in the
review process include potential ESBL-producing Enterobacter-
iaceae, fluoroquinolone-resistant (FQR) strains of gram-negative
bacilli and Streptococcus pneumoniae, MRSA, and vancomycin-
resistant enterococci. As the data are reviewed, clusters of 2 or
more isolates with a given resistance phenotype that are also
linked in time and space (hospital location) are flagged for im-
mediate confirmation of AST profile and identification and for
DNA fingerprinting.
The high throughput offered by the automated RiboPrinter
allows the generation of ribotype profiles for most organisms
within 1 day. The profile for each organism is matched against
all profiles in the RiboPrinter database, and each organism is
assigned to a ribogroup according to standardized criteria [18].
The RiboPrinter data are then reviewed, and if PFGE is required
for further discrimination, the organism is scheduled for PFGE
analysis. Once all work has been completed, the data are entered
into the SENTRY database and a report is generated and sent
to the submitting center. This process has been highly successful
in identifying clonal spread within clusters of MDR pathogens
(tables 4–6). Characterization of organisms with respect to anti-
microbial resistance genotype is usually performed later as
strains accumulate.
Hierarchical typing. The goals of molecular typing in a
surveillance program are often multiple. On the one hand, there
is a need to use a library typing system to monitor geographic
spread and prevalence shifts of epidemic and endemic clones
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Table 9. Epidemic cluster of extended-spectrum
b-lactamase–producing strains of Proteus mirabilis
causing pneumonia and bloodstream infection at a
single medical center in 1998.
Organism no.
Date of
culture
Molecular typing
Ribotype PFGE pattern
1 Apr 8 637-8a C
2 Apr 8 637-8 Z
3 Apr 30 637-8 Z
4 May 15 637-8 Z
5 Jun 16 637-8 Z
6 Oct 16 637-8 Z
7 Oct 16 637-8 Z
8 Oct 19 637-8 Z
9 Sep 18 1019-4b W
10 Oct 19 1019-4 W
11 Nov 5 1019-4 W
NOTE. The isoelectric focus results for each organism
were 5.4, 7.6, and 7.9. PFGE, pulsed-field gel electrophoresis.
Table is adapted from [19].
a Six strains from bloodstream infections at the same med-
ical center were observed with this same ribotype (637-8).
b One strain from a bloodstream infection at the same med-
ical center was observed with this same ribotype (1019-4).
Table 10. Molecular evaluation of van-
comycin-resistant Enterococcus faecium
producing urinary tract infections in 3
monitored medical centers.
Medical center
Molecular typing
Ribotype PFGE pattern
014 702-3 A
014 702-3 A
014 274-1 B
017 187-4 C
017 187-4 D
017 187-4 E
008 187-4 F
008 187-4 G
NOTE. PFGE, pulsed-field gel electrophoresis.
Table is adapted from [34].
over time [13, 14]. On the other hand, a comparative typing
method is useful to study smaller clusters of infection in greater
detail and with greater discriminatory power [18]. Finally, when
isolates with unusual or unique resistance phenotypes are de-
tected, it is necessary to determine the resistance genotype. Thus,
the flow of work in a large surveillance project such as SENTRY
proceeds in a hierarchical fashion, from the detailed review of
phenotypic data to the use of a library system such as ribotyping,
in order to provide a secondary level of discrimination, followed
by the use of a comparative typing system such as PFGE to further
delineate strains within a cluster sharing the same phenotypic
characteristics and ribotype. Resistance genotyping may be em-
ployed at any stage along this continuum to provide further
information regarding resistance mechanisms.
CLUSTERS OF RESISTANT ORGANISMS IN
SENTRY
In a review of the number of MDR clusters of organisms iden-
tified and molecularly characterized for SENTRY objective A
(bloodstream infections), objective C (pneumonia in hospital-
ized patients), and objective D (skin and soft-tissue infections),
it is clear that S. aureus is both the most prominent pathogen
in terms of total numbers of infections and an important no-
socomial pathogen with a high degree of nosocomial trans-
mission (tables 4–6). Between 50% and 92% of MDR-MRSA
clusters identified by phenotypic screening (same antibiogram,
isolated in same hospital during the same time frame) con-
tained evidence of clonal spread, based on a combination of
ribotype and PFGE profiles (tables 4–6).
Further analysis of MDR-MRSA isolates from bloodstream
infections has demonstrated a very broad spread of certain
clones, not only within a hospital or city but among geographic
regions (continents) as well [13, 14] (table 7; figure 1). For
example, the same MDR-MRSA clone (defined by ribotype and
PFGE profiles) has been observed in Brazil, Italy, and Portugal
(table 7). In individual institutions within these geographic
areas, local spread within hospitals was also observed [13]. A
number of additional examples of MDR-MRSA spread are de-
lineated by Diekema et al. [13, 14], and all serve to underscore
the importance of S. aureus, especially MDR-MRSA, as a global
pathogen. Persistent, comprehensive surveillance systems such
as SENTRY provide the opportunity to trace not only the MDR
phenotype but the major MDR genotypes as well [13].
Real-time analysis and reporting of these strains to individual
hospitals is an additional service of the SENTRY program and
may aid in the control of this important global pathogen.
Among the Enterobacteriaceae collected in the SENTRY pro-
gram, Escherichia coli and Klebsiella pneumoniae are the most
common MDR bloodstream infection pathogens causing clus-
ters of infections (tables 4–6); ∼50% of the recognized clusters
represent clonal spread. The instances of clonal spread are due
almost entirely to ESBL-producing strains, and most often the
infections originate in the urinary tract, bloodstream, or res-
piratory tract [25–27] (table 8). In most instances, clonal spread
of ESBL-producing strains is confined to a single institution or
to 1 city, but interinstitutional spread within a country or region
has also been observed. Notably, the spectrum of b-lactamase
enzymes identified by isoelectric focusing within each cluster
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Table 11. Molecular epidemiological analysis of multiply resistant isolates of Aci-
netobacter species (10 isolates), Pseudomonas aeruginosa (15 isolates), and Sten-
otrophomonas maltophilia (6 isolates) from patients hospitalized with pneumonia at
4 medical centers in 3 different countries.
Organism,
medical center Country
Specimen
type
Patient
in ICU
Molecular typing
Ribotype PFGE pattern
Acinetobacter species
039 Argentina SP Yes 815-2 Z
039 Argentina SP Yes 815-2 Z
039 Argentina IP Yes 815-2 Z
039 Argentina IP Yes 815-2 Z
039 Argentina SP Yes 815-2 Z
048 Brazil SP Yes 693-4 ND
048 Brazil SP Yes 693-4 Y
048 Brazil SP Yes 693-4 Y
048 Brazil SP Yes 693-4 Y
048 Brazil SP Yes 1008-2 ND
P. aeruginosa
039 Argentina SP Yes 1033-2 ND
041 Brazil IP No 1033-2 H
041 Brazil IP No 1033-3 H
041 Brazil IP No 1033-3 H
041 Brazil IP No 1034-2 ND
044 Colombia IP Yes 1003-2 ND
048 Brazil SP Yes 1004-2 ND
048 Brazil SP Yes 1005-7 ND
048 Brazil IP Yes 1005-1 G
048 Brazil SP Yes 1005-1 G
048 Brazil SP Yes 1005-1 G
048 Brazil SP Yes 1004-2 ND
048 Brazil SP Yes 559-4 G
048 Brazil SP Yes 559-4 G
048 Brazil SP Yes 559-4 G
S. maltophilia
041 Brazil IP No 1016-7 ND
041 Brazil IP No 191-6 ND
041 Brazil IP Yes 191-6 ND
041 Brazil IP NA 1019-5 ND
041 Brazil IP Yes 1019-7 ND
041 Brazil IP No 280-8 ND
NOTE. ICU, intensive care unit; IP, invasive pulmonary sample (bronchoalveolar lavage, protected
brush, or tracheal aspiration specimen); NA, not available; ND, not done; SP, sputum. Table is adapted
from [19].
is similar but may show some geographic variation, even within
a single clone (table 8).
Clusters of ESBL-producing Enterobacteriaceae are not lim-
ited to E. coli and K. pneumoniae [19]. An extensive cluster of
respiratory tract and bloodstream infections due to a single
strain of ESBL-producing Proteus mirabilis was identified in a
hospital in Argentina as a result of SENTRY surveillance efforts
(table 9). Such ongoing efforts are exactly the role that a global
surveillance program should play in assisting and augmenting
local infection-control efforts.
It is interesting that vancomycin-resistant enterococci have
not proved to be much of a problem with respect to clonal
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Table 12. Mutations in the quinolone-resistance-deter-
mining region of the gyr A gene among ciprofloxacin-sus-
ceptible Escherichia coli strains isolated from patients
with urinary tract infections in Latin America.
Nation
MIC of
ciprofloxacin, mg/mLa
gyr A
position
Amino acid
substitution
Brazil 0.015 NA None
Argentina 0.015 NA None
Argentina 0.15 NA None
Brazil 0.12 87 AsprGly
Chile 0.12 83 SerrLeu
Chile 0.12 87 AsprGly
Brazil 0.25 87 AsprAsn
Brazil 0.25 83 SerrLeu
Colombia 0.25 83 SerrLeu
Brazil 0.5 83 SerrLeu
Mexico 0.5 83 SerrLeu
Mexico 0.5 83 SerrLeu
NOTE. Susceptibility breakpoints determined by National Com-
mittee for Clinical Laboratory Standards criteria (1 mg/mL). Asn, as-
paragine; Asp, aspartic acid; Gly, glycine; Leu, leucine; NA, not appli-
cable; Ser, serine. Table is adapted from [21].
a MICs for 12 isolates selected from a total of 203 isolates sus-
ceptible to ciprofloxacin.
Table 13. Molecular characterization of fluoroquin-
olone-susceptible Streptococcus pneumoniae.
Years
No. of strains with indicated
trovafloxacin MIC, mg/mL
0.12 0.25 0.5 1
Strains tested
1994/95 37 12 1 0
1997/98 32 15 2 1
No. with mutations in
par C par E gyr A par C/gyr A
Results
1994/95 1 0 0 0
1997/98a 19 0 1 1
a Eighteen of 21 strains from 3 of 34 institutions.
spread within the SENTRY program. Only 2 instances of prob-
able clonal spread in 2 different institutions were recognized
among isolates from bloodstream infections (table 4). Addi-
tional clonal and sporadic spread of vancomycin-resistant en-
terococci among patients with urinary tract infections have also
been noted [34] (table 10).
A particularly diverse and highly resistant group of gram-
negative nosocomial pathogens includes the nonenteric gram-
negative bacilli, Pseudomonas aeruginosa, Acinetobacter species,
and Stenotrophomonas maltophilia. These organisms cause pri-
marily bloodstream and respiratory tract infections and are
often resistant to virtually every class of antimicrobial agents
[17, 36]. Clusters of MDR strains of P. aeruginosa causing
bloodstream infection, pneumonia, and urinary tract infection
have been recognized in the SENTRY system [17, 26, 34] (tables
4–6 and 11). These organisms are often resistant to carbape-
nems as well as b-lactams and aminoglycosides, and transmis-
sion of epidemic strains within individual medical centers has
been well documented [19] (table 11).
Similar patterns of infection with MDR clusters of Acineto-
bacter species and S. maltophilia have been noted, with clonal
spread—especially of Acinetobacter species—documented in pa-
tients with pneumonia and urinary tract infection [19, 34, 35]
(table 11). These organisms are ubiquitous in the hospital en-
vironment, and with the advent of more effective gram-positive
spectrum agents [37], they must be kept under careful scrutiny,
as they constitute a major infectious threat without adequate
current antimicrobial coverage [17, 36].
An additional means of providing molecular characterization
of resistant organisms in a surveillance program is by defining
the mechanism of resistance [21–23, 38]. In the SENTRY pro-
gram, in addition to providing phenotypic evidence of ESBL
production, the entire complement of b-lactamase enzymes
possessed by a given organism is determined with use of iso-
electric focusing [15] (tables 8 and 9). We have found that in
most instances ESBL-producing strains of Enterobacteriaceae
have at least 4 different b-lactamases [15] and that most but
not all of the time the b-lactamase profile is consistent with
the DNA fingerprint profile for a given cluster of ESBL-pro-
ducing gram-negative bacilli (tables 8 and 9). In some instances
differences in the b-lactamase profile may provide additional
insights into the molecular epidemiology of the MDR cluster
(table 8).
Likewise, although it is not difficult to identify phenotypically
strains of organisms with high-level resistance to fluoroquino-
lones, for unusual species such as Moraxella catarrhalis and
Haemophilus influenzae it is quite useful to characterize the
mutations in the QRDR that are responsible for resistance in
these organisms [23, 38]. Similarly, as part of a comprehensive
surveillance program, molecular characterization of first-stage
QRDR mutants may provide useful information (not readily
apparent on the basis of phenotypic methods) that allows one
to track the progress of first-stage and second-stage QRDR
mutants throughout specific microbial populations [21] (table
12). In the SENTRY program, we have done this for both E.
coli and S. pneumoniae (tables 12 and 13). The results are of
great concern and indicate rather extensive subpopulations of
apparently susceptible organisms (by phenotypic methods) that
may rapidly move into the resistant category, given the acqui-
sition of a second mutation [21].
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SUMMARY AND CONCLUSIONS
This overview demonstrates the very important role of molec-
ular characterization of organisms obtained during the course
of an antimicrobial resistance surveillance program. In order
to provide a comprehensive molecular characterization service,
the organisms themselves must be readily available. This illus-
trates the need for a central reference laboratory to serve as a
repository of organisms as well as a standardized source for all
microbial characterizations. We believe that the ability to have
organisms characterized both phenotypically and genotypically
provides levels of standardization, quality control, flexibility,
and responsiveness that are unequaled by any other surveillance
program design. The ability to provide molecular epidemiology
services to individual submitting centers is a significant “value-
added” aspect of the SENTRY program.
Likewise, the ability to utilize various methods to follow the
geographic spread of specific clones provides new information
and offers additional opportunities for research that may clarify
issues of pathogenesis and epidemiology. Finally, application of
molecular testing to define resistance mechanisms among the
different strains of bacteria may be useful in the evaluation of
resistance phenotypes, in the design of alternative agents, and
in predicting the emergence of groups of organisms with the
potential of high-level resistance to an entire class of anti-
microbial agents. Perhaps with the use of such information to
alter prescribing practices, the progression to high-level resis-
tance may be prevented, thus saving an entire class of highly
effective antimicrobial agents.
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